Keymed Biosciences Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Cash & Equivalents	709.91	851.03	604.07	1,521	199.41	432.67
Short-Term Investments	1,730	1,694	2,339	1,951	144.28	-
Trading Asset Securities	137.28	174.37	232.19	53.4	10.39	66.34
Cash & Short-Term Investments	2,577	2,719	3,175	3,525	354.08	499.01
Cash Growth	-13.50%	-14.37%	-9.91%	895.41%	-29.04%	-
Accounts Receivable	12.8	27.97	0.48	10.55	-	-
Other Receivables	27.99	18.5	34.01	0.72	0.84	1.17
Receivables	40.79	46.47	34.49	11.27	0.84	1.17
Inventory	95.95	61.1	51.33	22.43	11.33	3.31
Prepaid Expenses	-	-	-	-	-	13.28
Restricted Cash	-	1.78	-	-	-	-
Other Current Assets	74.85	111	48.83	23.67	14.66	1.65
Total Current Assets	2,788	2,940	3,310	3,582	380.92	518.41
Property, Plant & Equipment	946.38	893.74	584.43	177.53	124.82	125.37
Long-Term Investments	21.86	21.63	20.57	20.28	-	-
Other Intangible Assets	2.51	1.11	1.5	1.1	0.11	-
Other Long-Term Assets	46.36	26.91	15.84	153.59	24.1	14.81
Total Assets	3,805	3,883	3,932	3,934	529.95	658.58
Accounts Payable	30.07	29.49	14.91	2.78	3.42	3.48
Accrued Expenses	81.39	110.33	90.99	49.93	15.31	6.6
Short-Term Debt	337.84	105.04	60.79	0.55	42.37	47.75
Current Portion of Long-Term Debt	33.06	-	0.6	-	-	-
Current Portion of Leases	15.45	19.43	11.08	11.72	4.18	4.43
Current Income Taxes Payable	11.31	1.82	1.03	0.94	0.16	0.11
Current Unearned Revenue	-	-	-	1.61	10.87	1.44
Other Current Liabilities	50.55	48.08	200.3	44.54	3.93	7.79
Total Current Liabilities	559.66	314.18	379.7	112.08	80.24	71.59
Long-Term Debt	348.65	331.83	28.8	-	1,386	733.26
Long-Term Leases	16.34	21.62	20.93	26.99	20.31	24.27
Long-Term Unearned Revenue	243.18	228.19	163.67	8.72	6.79	1.59
Long-Term Deferred Tax Liabilities	0.46	0.28	-	-	-	-
Other Long-Term Liabilities	-	-	-	141.29	131.64	103.82
Total Liabilities	1,168	896.11	593.1	289.07	1,625	934.53
Common Stock	0.17	0.17	0.17	0.17	0.05	0.05
Additional Paid-In Capital	8,480	8,484	8,485	8,516	-	-
Retained Earnings	-5,986	-5,649	-5,290	-4,982	-1,095	-276
Comprehensive Income & Other	142.4	151.76	144.97	116.82	-	-
Total Common Equity	2,637	2,986	3,340	3,651	-1,095	-275.96
Minority Interest	0.44	0.5	-1.07	-5.59	-0.27	-
Shareholders' Equity	2,637	2,987	3,339	3,645	-1,095	-275.96
Total Liabilities & Equity	3,805	3,883	3,932	3,934	529.95	658.58
Total Debt	751.34	477.92	122.19	39.26	1,453	809.71
Net Cash (Debt)	1,825	2,241	3,053	3,485	-1,099	-310.7
Net Cash Growth	-31.05%	-26.59%	-12.40%	-	-	-
Net Cash Per Share	6.98	8.58	11.69	21.67	-16.37	-
Filing Date Shares Outstanding	275.6	276.6	277.39	279.74	271	-
Total Common Shares Outstanding	275.6	276.6	277.39	279.74	271	-
Working Capital	2,229	2,625	2,930	3,470	300.68	446.82
Book Value Per Share	9.57	10.80	12.04	13.05	-4.04	-
Tangible Book Value	2,634	2,985	3,339	3,650	-1,095	-275.96
Tangible Book Value Per Share	9.56	10.79	12.04	13.05	-4.04	-
Buildings	-	190.16	-	-	-	-
Machinery	-	626.77	235.49	110.64	82.14	67.98
Construction In Progress	-	34.48	323.55	21.63	0.18	0.54
Leasehold Improvements	-	60.77	51.73	42.45	42.68	38.07

Source: S&P Capital IQ. Standard template. Financial Sources.